Your browser is no longer supported. Please, upgrade your browser.
ZIOPHARM Oncology, Inc.
Index- P/E- EPS (ttm)-0.36 Insider Own6.56% Shs Outstand212.84M Perf Week11.08%
Market Cap733.10M Forward P/E- EPS next Y-0.41 Insider Trans-1.44% Shs Float200.24M Perf Month24.03%
Income-73.00M PEG- EPS next Q-0.10 Inst Own55.40% Short Float16.68% Perf Quarter32.95%
Sales- P/S- EPS this Y-173.40% Inst Trans-2.50% Short Ratio16.75 Perf Half Y4.78%
Book/sh0.68 P/B5.16 EPS next Y-10.80% ROA-44.60% Target Price- Perf Year-29.52%
Cash/sh0.65 P/C5.41 EPS next 5Y- ROE-50.00% 52W Range1.79 - 5.11 Perf YTD39.29%
Dividend- P/FCF- EPS past 5Y-17.40% ROI- 52W High-31.31% Beta2.08
Dividend %- Quick Ratio8.00 Sales past 5Y- Gross Margin- 52W Low95.54% ATR0.23
Employees73 Current Ratio8.00 Sales Q/Q- Oper. Margin- RSI (14)67.64 Volatility7.79% 7.47%
OptionableYes Debt/Eq0.00 EPS Q/Q78.00% Profit Margin- Rel Volume1.85 Prev Close3.51
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume1.99M Price3.51
Recom2.20 SMA2020.73% SMA5025.64% SMA20022.53% Volume3,695,988 Change0.00%
Jun-19-20Initiated Jefferies Buy $7
Mar-04-20Initiated Cantor Fitzgerald Overweight $6
Aug-23-19Resumed Raymond James Outperform
Apr-04-19Initiated Lake Street Buy $7
Apr-01-19Initiated Laidlaw Buy $7.50
Nov-15-18Upgrade Raymond James Mkt Perform → Outperform
Jun-18-18Downgrade JP Morgan Neutral → Underweight
Jun-01-17Initiated H.C. Wainwright Buy $9.50
Aug-10-16Upgrade Wells Fargo Underperform → Market Perform
Jul-19-16Reiterated Mizuho Neutral $7 → $5
Jun-02-16Initiated Raymond James Mkt Perform
May-11-16Reiterated Mizuho Neutral $6 → $7
Jan-25-16Reiterated Mizuho Neutral $10 → $6
Dec-04-15Initiated Wells Fargo Underperform
Jun-10-15Reiterated Mizuho Neutral $14 → $10
Mar-10-15Downgrade Mizuho Buy → Neutral $14
Mar-02-15Reiterated Mizuho Buy $11 → $14
Mar-20-14Initiated Mizuho Buy $11
Apr-02-12Reiterated Griffin Securities Buy $9 → $12
Mar-26-12Initiated Canaccord Genuity Buy $9
Jan-14-21 08:00AM  
Dec-23-20 04:01PM  
Dec-22-20 07:45AM  
Dec-21-20 04:01PM  
Dec-17-20 09:00AM  
Dec-16-20 04:01PM  
Dec-15-20 07:52AM  
Dec-14-20 04:02PM  
Dec-12-20 05:15PM  
Dec-11-20 06:57PM  
Dec-10-20 07:01PM  
Dec-08-20 09:00AM  
Dec-04-20 08:30AM  
Dec-02-20 10:04PM  
Nov-28-20 05:30PM  
Nov-27-20 05:32PM  
Nov-25-20 08:30PM  
Nov-24-20 09:00AM  
Nov-20-20 11:00AM  
Nov-19-20 09:30AM  
Nov-17-20 04:15PM  
Nov-16-20 08:30AM  
Nov-13-20 09:15AM  
Nov-12-20 09:00AM  
Nov-06-20 10:31PM  
Nov-05-20 04:02PM  
Nov-02-20 09:00AM  
Oct-29-20 09:00AM  
Oct-16-20 04:00PM  
Sep-30-20 06:26PM  
Sep-23-20 01:48PM  
Sep-22-20 08:30AM  
Sep-15-20 08:30AM  
Sep-14-20 04:17PM  
Sep-10-20 09:00AM  
Sep-07-20 09:58AM  
Aug-06-20 04:04PM  
Jul-28-20 09:00AM  
Jul-22-20 08:30AM  
Jul-10-20 07:25AM  
Jul-09-20 04:15PM  
Jul-08-20 08:30AM  
Jun-30-20 11:47PM  
Jun-22-20 09:48AM  
Jun-15-20 08:33AM  
Jun-12-20 09:00AM  
May-29-20 08:00AM  
May-27-20 04:15PM  
May-11-20 02:50PM  
May-08-20 04:00PM  
May-07-20 04:05PM  
Apr-30-20 08:00AM  
Apr-27-20 08:30AM  
Apr-06-20 06:00AM  
Mar-04-20 12:37PM  
Mar-02-20 04:05PM  
Feb-28-20 08:30AM  
Feb-24-20 08:30AM  
Feb-05-20 09:03AM  
Feb-04-20 04:01PM  
Jan-30-20 08:45AM  
Dec-30-19 08:56AM  
Dec-19-19 08:45AM  
Dec-11-19 11:23AM  
Dec-09-19 05:00PM  
Dec-08-19 09:00AM  
Dec-06-19 08:00AM  
Nov-23-19 09:00AM  
Nov-19-19 03:31PM  
Nov-18-19 07:00AM  
Nov-11-19 09:10AM  
Nov-07-19 04:05PM  
Oct-30-19 08:30AM  
Oct-28-19 06:06PM  
Oct-18-19 06:00AM  
Oct-15-19 08:00AM  
Oct-11-19 12:49PM  
Oct-01-19 08:00AM  
Sep-30-19 06:45AM  
Sep-03-19 02:21PM  
Aug-28-19 04:05PM  
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Buck JillEVP, GM Gene TherapyJan 08Sale3.1227,89487,029199,516Jan 12 04:35 PM
Lafond Kevin GSVP, Treasurer & CAOJan 08Sale3.0918,02055,68263,965Jan 12 04:34 PM
Hadfield RobertGeneral Counsel and SecretaryJan 08Sale3.1226,50082,680133,319Jan 12 04:33 PM
De Groot EleanorEVP, GM Cell TherapyJan 04Sale2.7221,62058,806206,413Jan 06 05:03 PM
Cooper Laurence James NeilPresident and CEOJan 04Sale2.71105,693286,4281,799,280Jan 06 05:02 PM